Clinical Study of (A-319) in the Treatment of Active Rheumatoid Arthritis

This study is testing a new drug called A-319 for people with active rheumatoid arthritis (RA) — a condition where the immune system attacks the joints, causing pain, swelling, and stiffness — who have not responded well to existing biological or targeted treatments. **You may be eligible if...** - You are 18–70 years old with a diagnosis of rheumatoid arthritis for at least 24 weeks - You have tried at least one conventional RA drug (like methotrexate) and at least one advanced biological or targeted drug without enough benefit - You still have significant joint swelling and tenderness (at least 6 tender and 4 swollen joints) - Your disease activity is moderate to severe based on standard measurements **You may NOT be eligible if...** - You have another autoimmune disease that would affect the study - You have active tuberculosis, active hepatitis B or C, or HIV - You have had a recent heart attack, severe heart failure, or major surgery in the past 4 weeks - You have had certain RA drugs (like rituximab) very recently - You have cancer in the past 5 years (with some exceptions) Talk to your doctor to see if this trial is right for you.